Monday, 16 March 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 16 March 2026
News

$57M J&J drug under threat

Posted 16 March 2026 AM

Cipla has become the first company to register a generic version of Johnson & Johnson’s PBS listed oral pulmonary arterial hypertension (PAH) treatment Opsumit.

In 2025, Opsumit earned J&J $57.6 million in pre-rebate PBS benefits, an eight per cent year-on-year decrease.

To see the whole article, please login

Popular

Last ditch effort to keep exclusivity
CEO flying in for Aussie TV spot
New PBS drug pulls out of Australia
New drug disappears from PBS
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home